Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $52.00

Roivant Sciences (NASDAQ:ROIV) had its price target upped by Jefferies Financial Group from $42.00 to $52.00 in a report published on Tuesday, Marketbeat.com reports. The brokerage currently has a buy rating on the stock.

ROIV has been the subject of several other reports. Sanford C. Bernstein raised shares of Roivant Sciences to a “strong-buy” rating in a research note on Wednesday, July 29th. Bank of America reissued a “neutral” rating on shares of Roivant Sciences in a research report on Friday, July 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Roivant Sciences in a report on Wednesday, August 19th. Citigroup boosted their price objective on Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a report on Monday, August 10th. Finally, Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a report on Thursday, May 21st. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Roivant Sciences has an average rating of “Moderate Buy” and an average target price of $40.62.

Roivant Sciences Stock Down 2.1%

Roivant Sciences stock opened at $40.94 on Tuesday. The company’s 50-day moving average price is $35.68 and its 200-day moving average price is $31.56. The company has a market cap of $29.57 billion, a PE ratio of -77.25 and a beta of 1.12. Roivant Sciences has a twelve month low of $13.81 and a twelve month high of $42.50.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The company had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. As a group, sell-side analysts expect that Roivant Sciences will post -2 earnings per share for the current fiscal year.

Insider Activity at Roivant Sciences

In related news, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total value of $6,632,000.00. Following the completion of the transaction, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at $53,489,169.08. The trade was a 11.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mayukh Sukhatme sold 284,707 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $36.25, for a total value of $10,320,628.75. Following the sale, the insider owned 18,630,739 shares of the company’s stock, valued at approximately $675,364,288.75. This represents a 1.51% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,055,913 shares of company stock valued at $107,261,258 over the last ninety days. 8.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors have recently added to or reduced their stakes in ROIV. California State Teachers Retirement System boosted its holdings in shares of Roivant Sciences by 4,212.2% in the 2nd quarter. California State Teachers Retirement System now owns 19,001,068 shares of the company’s stock valued at $672,448,000 after buying an additional 18,560,434 shares in the last quarter. Morgan Stanley grew its position in shares of Roivant Sciences by 31.7% in the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after buying an additional 14,036,696 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Roivant Sciences by 365.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock worth $238,323,000 after acquiring an additional 8,621,567 shares in the last quarter. Norges Bank bought a new position in shares of Roivant Sciences during the 4th quarter worth approximately $112,750,000. Finally, Jefferies Financial Group Inc. purchased a new stake in Roivant Sciences during the fourth quarter valued at approximately $76,272,000. Institutional investors own 64.76% of the company’s stock.

Key Stories Impacting Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Roivant’s Pulmovant reported positive Phase 2 results for mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD). The treatment produced a reported 56.3% placebo-adjusted reduction in pulmonary vascular resistance, and Roivant has begun the Phase 3 PHrontier trial. The results strengthen the case for a potentially important new therapy and were the primary reason for the recent rally. Roivant Reports Positive Mosliciguat Phase 2 Results
• Positive Sentiment: Jefferies raised its price target for ROIV to $52 from its prior target, while H.C. Wainwright increased its target to $47. The revisions signal continued analyst confidence following the mosliciguat data. Jefferies Raises Roivant Price Target H.C. Wainwright Raises Roivant Price Target
• Positive Sentiment: Large call-option activity and reports that hedge-fund ownership rose 41% in the second quarter indicate strong investor interest and bullish positioning, although options activity can also increase volatility. Roivant Call Option Activity
• Neutral Sentiment: Roivant presented at Citigroup’s Biopharma Back to School Summit and the Cantor Fitzgerald Global Healthcare Conference. These events may provide additional pipeline commentary, but the available reports do not identify a new material announcement. Citigroup Summit Transcript
• Negative Sentiment: The stock’s retreat appears to reflect profit-taking after reaching a record high near $42.50, rather than a clearly negative company-specific announcement. Roivant remains loss-making, and its valuation leaves the shares sensitive to clinical-trial execution and future regulatory risk.

About Roivant Sciences

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions.

Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support.